Mechanism of the Sympathoinhibition Produced by the Clonidine‐Like Drugs Rilmenidine and Moxonidine
1999; Wiley; Volume: 881; Issue: 1 Linguagem: Inglês
10.1111/j.1749-6632.1999.tb09367.x
ISSN1749-6632
AutoresBéla Szabó, Christina Bock, Ulrich Nordheim, Nathalie Niederhoffer,
Tópico(s)Organic and Inorganic Chemical Reactions
ResumoAnnals of the New York Academy of SciencesVolume 881, Issue 1 p. 253-264 Mechanism of the Sympathoinhibition Produced by the Clonidine-Like Drugs Rilmenidine and Moxonidine BELA SZABO, Corresponding Author BELA SZABO Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., Germany Phone, +49–761-203–5312; fax, +49–761-203–5318; e-mail, [email protected]Search for more papers by this authorCHRISTINA BOCK, CHRISTINA BOCK Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., GermanySearch for more papers by this authorULRICH NORDHEIM, ULRICH NORDHEIM Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., GermanySearch for more papers by this authorNATHALIE NIEDERHOFFER, NATHALIE NIEDERHOFFER Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., GermanySearch for more papers by this author BELA SZABO, Corresponding Author BELA SZABO Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., Germany Phone, +49–761-203–5312; fax, +49–761-203–5318; e-mail, [email protected]Search for more papers by this authorCHRISTINA BOCK, CHRISTINA BOCK Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., GermanySearch for more papers by this authorULRICH NORDHEIM, ULRICH NORDHEIM Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., GermanySearch for more papers by this authorNATHALIE NIEDERHOFFER, NATHALIE NIEDERHOFFER Department of Pharmacology, University of Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg i. Br., GermanySearch for more papers by this author First published: 06 February 2006 https://doi.org/10.1111/j.1749-6632.1999.tb09367.xCitations: 23Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Kobinger, W. 1978. Central α-adrenergic systems as targets for hypotensive drugs. Rev. Physiol. Biochem. Pharmacol. 81: 40– 100. 2 Guyenet, P. G., 1997. Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites? Am. J. Physiol. 273: R1580– R1584. 3 Bousquet, P., J. Feldman & J. Schwartz. 1984. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230: 232– 236. 4 Ernsberger, P. & M. A. Haxhiu. 1997. The I1-imidazoline binding site is a functional receptor mediating vasodepression via the ventral medulla. Am. J. Physiol. 273: R1572– R1579. 5 De Jonge, A., P. B. M. W. M. Timmermans & P. A. Van Zwieten. 1981. Participation of cardiac presynaptic α2-adrenoceptors in the bradycardiac effects of clonidine and analogues. Naunyn-Schmiedeberg's Arch. Pharmacol. 317: 8– 12. 6 Laubie, M. et al. 1985. Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S3341), an α2 adrenoceptor agonist. J. Pharmacol. (Paris) 16: 259– 278. 7 Van Zwieten, P. A., et al. 1986. Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. Arch. Int. Pharmacodyn. 279: 130– 149. 8 Armah, B. I., 1988. Unique presynaptic α2-receptor selectivity and specificity of the antihypertensive agent moxonidine. Arzneimittelforschung 38: 1435– 1442. 9 Ernsberger, P. et al. 1987. Clonidine binds to imidazole binding sites as well as α2-adrenoceptors in the ventrolateral medulla. Eur. J. Pharmacol. 134: 1– 13. 10 Ernsberger, P. et al. 1990. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J. Pharmacol. Exp. Ther. 253: 408– 418. 11 Bricca, G. et al. 1993. Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem. Br. J. Pharmacol. 110: 1537– 1543. 12 Szabo, B. et al. 1995. Cardiovascular effects of agmatine, a "clonidine-displacing substance", in conscious rabbits. Naunyn-Schmiedeberg's Arch. Pharmacol. 351: 268– 273. 13 Szabo, B. et al. 1987. ACTH increases noradrenaline release in pithed rabbits with electrically stimulated sympathetic outflow. Eur. J. Pharmacol. 136: 391– 399. 14 Feldman, J. et al. 1990. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br. J. Pharmacol. 100: 600– 604. 15 Tibiriça, E. et al. 1991. An imidazoline-specific mechanism for the hypotensive effect of clonidine: A study with yohimbine and idazoxan. J. Pharmacol. Exp. Ther. 256: 606– 613. 16 Gomez, R. E., et al. 1991. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Eur. J. Pharmacol. 195: 181– 191. 17 Mayorov, D., M. Chernobelski & O. Medvedev. 1993. Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats. J. Cardiovasc. Pharmacol. 22: 314– 320. 18 Haxhiu, M. A., et al. 1994. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. 24: S1– S8. 19 Timmermans, P. B. M. W. M., et al. 1981. Characterization of α-adrenoceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. Eur. J. Pharmacol. 70: 7– 15. 20 Tibirica, E., J. Feldman & P. Bousquet. 1988. Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. J. Pharmacol. Exp. Ther. 244: 1062– 1066. 21 Hieble, J. P., &D. C. Kolpak. 1993. Mediation of the hypotensive action of systemic clonidine in the rat by α2-adrenoceptors. Br. J. Pharmacol. 110: 1635– 1639. 22 Szabo, B., R. Urban & K. Starke. 1993. Sympathoinhibition by rilmenidine in conscious rabbits: Involvement of α2-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 348: 593– 600. 23 Urban, R., B. Szabo & K. Starke. 1994. Is the sympathoinhibitory effect of rilmenidine mediated by α-2 adrenoceptors or imidazoline receptors? J. Pharmacol. Exp. Ther. 270: 572– 578. 24 Urban, R., B. Szabo & K. Starke. 1995. Involvement of α2-adrenoceptors in the cardiovascular effects of moxonidine. Eur. J. Pharmacol. 282: 19– 28. 25 Sannajust, F. & G. A. Head. 1994. Rilmenidine-induced hypotension in conscious rabbits involves imidazoline-preferring receptors. J. Cardiovasc. Pharmacol. 23: 42– 50. 26 Chan, C. K. S., F. Sannajust & G. A. Head. 1996. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J. Pharmacol. Exp. Ther. 276: 411– 420. 27 MacMillan, L. B., et al. 1996. Central hypotensive effects of the α2A-adrenergic receptor subtype. Science 273: 801– 803. 28 Zhu, Q.-M. et al. 1999. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N α2A-adrenoceptor transgenic mice. Br. J. Pharmacol. 126: 1522– 1530. 29 Munk, S. A., et al. 1996. Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: A potent imidazoline1 receptor specific agent. J. Med. Chem. 39: 1193– 1195. 30 Tibiriça, E. et al. 1989. Correlation between the inhibitory effect on catecholaminergic ventrolateral medullary neurons and the hypotension evoked by clonidine: A voltammetric approach. J. Pharmacol. Exp. Ther. 250: 642– 647. 31 Tibiriça, E. et al. 1991. Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors. Eur. J. Pharmacol. 209: 213– 221. 32 Brown, M. J., &D. Harland. 1984. Evidence for a peripheral component in the sympatholytic effect of clonidine in rats. Br. J. Pharmacol. 83: 657– 665. 33 Warren, J. B., et al. 1991. Assessment of MK-467, a peripheral α2-adrenergic receptor antagonist, with intravenous clonidine. Clin. Pharmacol. Ther. 50: 71– 77. 34 Garty, M. et al. 1990. Effects of clonidine on renal sympathetic nerve activity and norepinephrine spillover. J. Pharmacol. Exp. Ther. 254: 1068– 1075. 35 Conway, E. L., &B. Jarrott. 1980. Clonidine distribution in the rat: Temporal relationship between tissue levels and blood pressure response. Br. J. Pharmacol. 71: 473– 478. 36 Armah, B. I., E. Hofferber & W. Stenzel. 1988. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforschung 38: 1426– 1434. 37 Laurent, S. & M. Safar. 1992. Rilmenidine: A novel approach to first-line treatment of hypertension. Am. J. Hypertens. 5: 99S– 105S. 38 Prichard, B. N. C. &B. R. Graham. 1996. Effective antihypertensive therapy: Blood pressure control with moxonidine. J. Cardiovasc. Pharmacol. 27: S38– S48. Citing Literature Volume881, Issue1IMIDAZOLINE RECEPTORS AND THEIR ENDOGENOUS LIGANDS: CURRENT CONCEPTS AND THERAPEUTIC POTENTIALJune 1999Pages 253-264 ReferencesRelatedInformation
Referência(s)